- Residency - UT Southwestern Medical Center (2002-2006), Urology
- Internship - UT Southwestern Medical Center (2001-2002), General Surgery
- Medical School - UT Southwestern Medical School
- Fellowship - UT MD Anderson Cancer Center (2006-2009), Urologic Oncology
Vitaly Margulis, M.D.
- Genitourinary Cancer
- Kidney Cancer
Vitaly Margulis, M.D., Professor of Urology at UT Southwestern Medical Center, graduated with honors from the University of Texas at Austin and UT Southwestern Medical School. He trained in the highly competitive urology residency program at UT Southwestern and completed a fellowship in urologic oncology at the University of Texas MD Anderson Cancer Center in Houston, where he was previously a Clinical Specialist in Urologic Oncology. He joined the UT Southwestern faculty in 2009.
An expert surgeon, Dr. Margulis uses minimally invasive techniques to treat patients with soft-tissue tumors and kidney, prostate, bladder, testicular, penile, and adrenal cancers. His research projects include clinical and lab research focused on the biology of kidney cancer, the genetic changes that occur and cause it to spread, and how to stop it.
Dr. Margulis travels frequently to lecture on urologic care and
procedures. He is a Fellow of the American College of Surgeons and a
member of the Society of Urologic Oncology, Endourologic Society,
American Urological Association, American Medical Association, Texas
Medical Association, Texas Urologic Association, Dallas County Medical
Society, and Harris County Medical Society.
He has authored several book chapters and published research in a variety of medical journals, including the Journal of the National Cancer Institute, Journal of Clinical Oncology, Urologic Oncology, Clinical Cancer Research, Oncogene, Cancer, Cancer Epidemiology, Biomarkers and Prevention, Urology, Journal of Urology, and British Journal of Urology. He also serves as a reviewer for those publications.
In 2018, Dr. Margulis was included in D Magazine's Best Doctors list as well as Texas Monthly's Super Doctors list.
Dr. Margulis spent his childhood in Russia and Italy. He enjoys literature, music, traveling, and spending time with his wife and daughter. He’s also an avid scuba diver and likes exploring the depths of the Great Barrier Reef in Australia.
Meet Dr. Margulis
Vitaly Margulis, M.D., believes in working smarter, not harder, and he applies that philosophy to cancer care.
"UT Southwestern is on the leading edge of surgical expertise, and our multidisciplinary care translates into better outcomes."
“I know my patients want to get on with their lives, so I strive for maximum results with minimal treatment,” he says. “I’m always looking for ways to make surgery smarter or achieve the same result with, for example, four cycles of chemotherapy rather than 10.”
A Professor of Urology at UT Southwestern Medical Center, Dr. Margulis uses robotics, laparoscopy, focal therapy, and open surgical techniques to treat soft-tissue tumors and kidney, prostate, bladder, testicular, penile, and adrenal cancers. His primary interest, however, is kidney cancer, and he is studying the genetic changes of the disease, what causes it to spread, and how to stop it.
Dr. Margulis considers himself a shepherd who merely guides and gives medical advice. Patients, he says, have the most important role on his team. He believes they respond better to treatment when they are part of the equation.
He also treats each patient as an individual and views his or her cancer as a separate entity.
“Personalized cancer management is what patients are looking for,” he says. “This is the future of medicine, which we try to deliver now.”
- Society of Urologic Oncology
- Endourologic Society
- American Urological Association
- American Society of Clinical Oncology
- American Association for Cancer Research
- American College of Surgeons
- American Medical Association
- Texas Medical Association
- Dallas County Medical Society
- Harris County Medical Society
- Alpha Omega Alpha 2001, UT Southwestern Medical School
- Ruth L. Kirschstein National Research Service Award 2006, University of Texas MD Anderson Cancer Center
- American Urological Association Foundation Research Scholar Award 2006, AFUD/AUA
- National Institute of Health Clinical Research Scientist LRP Award 2007, NIH
- Merit Award 2008, American Society of Clinical Oncology
- NIH Clinical Research Scientist LRP Award 2009, National Institute of Health
- American Urological Association / Japanese Urologic Association Academic Exchange Scholar 2012, American Urological Association
- Best Doctors in America 2017, Best Doctors Polling and Research (Peer Selected)
- Detection of Invasive Renal Cell Carcinoma with Targeted SPA0003043 2019, American Urological Association
Predictors of oncologic outcome after resection of locally recurrent renal cell carcinoma
Margulis V, McDonald M, Matin SF, et al The Journal of Urology April 2009 Issue 4, Volume 181 496
Multi-institutional external validation of the predictive value of Ki-67 labeling index in patients treated with radical cystectomy
Margulis V, Karakiewicz P, Fradet Y, et al Journal of the National Cancer Institute January 2009 Volume 101, Number 2 114-119
Surgical morbidity associated with administration of targeted molecular therapy prior to cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma
Margulis V, Matin SF, Tannir N, et al The Journal of Urology July 2008 180, 1 94-98
Genetic Susceptibility to Renal Cell Carcinoma: The Role of DNA Double Strand Break Repair Pathway
Margulis V, Lin J, Hushan Y, et al Cancer Epidemiology, Biomarkers & Prevention September 2008 17 2366
Type III TGF-β Receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-β signaling pathway
Vitaly Margulis, Tapati Maity, Xiu-Ying Zhang, et. al Clinical Cancer Research September 2008 14 5722-5730
Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses
Woldu Sl, Aydin AM, Rao AV, Hutchinson RC, Singla N, Clinton TN, Krabbe LM, Passoni NM, Raj GV, Miller DS, Amatruda JF, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Bagrodia A. 2017
Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract.
Wirth GJ, Haitel A, Moschini M, Soria F, Klatte T, Hassler MR, Bensalah K, Briganti A, Karam JA, Lotan Y, Margulis V, Raman JD, Remzi M, Rioux-Leclercq N, Robinson BD, Rouprêt M, Wood CG, Shariat SF World journal of urology 2016 Oct
The Utility of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance.
Canvasser NE, Stouder K, Lay AH, Gahan JC, Lotan Y, Margulis V, Raj GV, Sagalowsky AI, Cadeddu JA The Journal of urology 2016 Feb
Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma.
Wang ZR, Wei JH, Zhou JC, Haddad A, Zhao LY, Kapur P, Wu KJ, Wang B, Yu YH, Liao B, He DL, Chen W, Margulis V, Hsieh JT, Luo JH Oncotarget 2016 Apr
Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) is Associated with Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract.
Raman JD, Warrick JI, Caruso C, Yang Z, Shuman L, Bruggeman RD, Shariat S, Karam JA, Wood C, Weizer AZ, Remzi M, Haitel A, Bensalah K, Rioux-Leclerq N, Bolenz C, Roscigno M, Krabbe LM, Kapur P, Lotan Y, Margulis V, DeGraff DJ Urology 2016 May
Impact of Hospital caseVolume on Testicular Cancer Outcomes and Practice Patterns
Woldu SL, Matulay JT, Clinton TN, Singla N, Krabbe LM, Hutchinson RC, Sagalowsky A, Lotan Y, Margulis V, Bagrodia A. 2017
Oncology: Adrenal/Renal/Upper Tract/Bladder Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma
Krabbe LM, Heitzplatz B, Presuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercg N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensaleh K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V. 2017
Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases
Wang CJ, Christie A, Lin M, Jung M, Weix D, Huelsmann L, Kuhn K, Meyer J, Desai N, Kim DW, Pedrosa I, Margulis V, Cadeddu J, Sagalowsky AI, Gahna J, Laine A, Xie X, Choy H, Brugarolas J, Timmerman R, Hannan R. 2017
Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma.
Mandalapu RS, Remzi M, de Reijke TM, Margulis V, Palou J, Kapoor A, Yossepowitch O, Coleman J, Traxer O, Anderson JK, Catto J, de la Rosette J, O'Brien T, Zlotta A, Matin SF World journal of urology 2016 May
Role of Survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study.
Mathieu R, Lucca I, Vartolomei MD, MBeutcha A, Klatte T, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Montorsi F, Briganti A, Rouprêt M, Margulis V, Rink M, Rieken M, Kenner L, Susani M, Wolgang L, Shariat SF BJU international 2016 Mar
HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC).
Soria F, Moschini M, Haitel A, Wirth GJ, Karam JA, Wood CG, Rouprêt M, Margulis V, Karakiewicz PI, Briganti A, Raman JD, Kammerer-Jacquet SF, Mathieu R, Bensalah K, Lotan Y, Özsoy M, Remzi M, Gust KM, Shariat SF World journal of urology 2016 Jun
Do Referral Patterns in Adolescents and Young Adults with Testicular Cancer Impact Oncologic Outcomes?
Cost NG, Caldwell BT, Adibi M, Raj GV, Sagalowsky AI, Margulis V Journal of adolescent and young adult oncology 2016 Feb
Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study.
Favaretto RL, Bahadori A, Mathieu R, Haitel A, Grubmüller B, Margulis V, Karam JA, Rouprêt M, Seitz C, Karakiewicz PI, Cunha IW, Zequi SC, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Jacquet-Kammerer S, Bensalah K, Lotan Y, Bachmann A, Rink M, Briganti A, Shariat SF World journal of urology 2016 Apr
Magnetic Resonance Imaging?guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate
Costa D, Goldberg K, de Leon A, Lotan Y, XI Y, Aziz M, Frefeld Y, Margulis V, Raj G, Roehrborn CG, Hornberger B, Desai N, Bagrodia A, Francis F, Pedrosa I, Cadeddu J. 2019
Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study.
Mathieu R, Klatte T, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Scherr DS, Montorsi F, Briganti A, Rouprêt M, Margulis V, Rink M, Kluth LA, Rieken M, Kenner L, Susani M, Robinson BD, Xylinas E, Loidl W, Shariat SF BJU international 2015 Jul
Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus
Freifeld Y, Margulis V, Woldu S, Timmerman R, Brugarolas J, Hannan R. 2019
Detection of invasive renal cell carcinoma with targeted molecular imaging
Margulis V, Hammers H, Sun X, Taneja S, Salzer J. 2019
A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States
Singla N, Fang D, Su X, Bao Z, Cao Z, Jafri SM, Xiong G, Zhang L, Hutchinson R, Sagalowsky AI, Lotan Y, Li X, Zhou L, Raman JD, Margulis V 2017
Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. Urologic Oncology: Seminars and Original Investigations
Freifeld Y, Xi Y, Passoni N, Woldu S, Hornberger B, Goldberg K, Bagrodia A, Raj G, Margulis V, Cadeddu J, Lotan Y, Francis F, Pedrosa I, Roehrborn CG, Costa D. 2018
- Predictors of oncologic outcome after resection of locally recurrent renal cell carcinoma
- Molecular biology involved in renal cell cancer tumorigenesis
- Metastatic progression and resistance to targeted therapies
- Genitourinary Cancer
- Kidney Cancer
- Male Urology
- Prostate Cancer
- Testicular Cancer
- Surgery for Genitourinary Cancer
- Genitourinary Surgery